PROS1 and cancer: This could partly explain the differences in apoptosis induction between the two treatments since the lower effectiveness of selumetinib+capivasertib could be due to the adaptation of cancer cells to therapy through the MCL-1 antiapoptotic protein (Supplementary Figure S1).